NaluBio, Inc.
4 known investors
Nalu Bio develops an AI-powered drug discovery platform targeting the endocannabinoid system to create therapeutics for inflammatory, immune, and metabolic diseases. The company designs novel, non-addictive ECS-based solutions for patients with conditions like chronic pain, sleep disorders, and endometriosis.
Founders & leadership
CK
Caitlyn KrebsCo-founder + CEO
PW
Phyllis WhiteleyCo-founder + Board Member
RU
Randall UsseryCo-founder + Board Member
PE
Phyllis E. WhiteleyExecutive Officer, Director
HG
Howard GoodwinDirector
RS
Randall S. UsseryDirector
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$4.8MraisedMar 2023 · 11 investors · OtherRule 506(b)
▶$4.8MraisedMar 2023 · 11 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Phyllis E. WhiteleyExecutive Officer, Director
- Howard GoodwinDirector
- Randall S. UsseryDirector
- Caitlyn KrebsExecutive Officer, Director
- Offering amount
- $17.1M
- Amount sold
- $4.8M
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.